티앤알바이오팹, 1분기 매출 87억···전년 대비 46% 증가

T&R Biofab demonstrates impressive revenue growth through its specialized 3D bioprinting technology, reflecting expanding commercialization in the regenerative medicine sector. Despite the top-line surge, the company faces a critical need to bridge the gap between rapid scaling and sustainable profitability amidst significant financial liabilities.